Key Investor Signals
Reagents used at DKFZ and university research labs
Scientists at DKFZ, Heidelberg University Hospital and University Hospital Erlangen use BlueRay reagents in hematology and cell-therapy research workflows.
More than €1M awarded through EXIST Forschungstransfer
BlueRay’s project was selected for more than €1 million through EXIST Forschungstransfer, with Mohamed Awwad leading the funded project at Heidelberg University Hospital.
More than 2,000 CAR-T samples analysed in development
Analytical development spans different CAR designs, receptor densities and spacer formats. CD19 dilution experiments detected CAR-positive populations down to 0.06%.
Other Positive Signals
- Offers in-stock CD19 and BCMA research detection reagents in 30-test kits with PE and biotin formats.
- Recognized as a Heidelberg University spin-off through its Created at Heidelberg University label.
Team
Mohamed Hemaid Sayed Awwad
Co-founder & Managing Director
- Leads translational immunology research as a Group Leader and Senior Scientist at Heidelberg University Hospital.
- Brings over a decade of research experience, including projects on T-cell dysfunction in cancer and standardized diagnostics.
- Combines a PhD in Cancer Immunology with an MBA from Frankfurt School and lectures in Immuno-Oncology at Heidelberg.
Michael Hundemer
Co-founder
- Has led Heidelberg University Hospital’s Cell Therapy Laboratory since 2006, bringing two decades of direct cell-therapy experience.
- Heads clinical flow cytometry and hematological diagnostics laboratories at Heidelberg University Hospital.
- Researches T-cell immunology and multiple myeloma, directly overlapping BlueRay’s CAR-T detection focus.
Product
BlueRay Precision’s SCOPE platform uses ready-to-use reagents to identify CAR-expressing cells by flow cytometry. Engineered antigen proteins bind the target receptor, while controlled fluorescent labeling is designed to improve staining consistency across reagent batches.
Recognition across CAR designs
CD19 and BCMA antigen-based reagents bind the matching CAR recognition domain. Antigen and spacer engineering support detection across different receptor architectures, rather than relying on a single hinge design.
Controlled staining chemistry
An engineered Fc region is designed to limit nonspecific staining. Site-specific labeling and controlled fluorochrome-to-protein ratios aim to reduce lot-dependent variation in the fluorescence signal.
Standard laboratory workflow
The staining protocol uses 3 microlitres of reagent per test with a 15-minute incubation, followed by washing and flow-cytometer analysis. Researchers can combine it with other cell-identification antibodies.
Market Overview
CAR-T treatment is expanding beyond specialist trials into routine care for blood cancers, while research is extending to autoimmune disease. Laboratories need to characterize engineered cells during development and follow them over time. Differences in staining and analysis complicate comparisons between research sites.
The buyers for standardized detection tools include academic laboratories, biotechnology companies and cell-therapy developers. Established flow cytometers allow new reagents to fit existing equipment, while consumables support repeat purchasing. Research-use suppliers must still demonstrate reproducibility and compete with established reagent vendors.
Patients receiving CAR-T therapy in 2024 across countries covered by the EBMT activity survey.
Share of the global genetically modified cell-therapy pipeline using CAR-T in Q2 2026.
Global net trade sales of the BCMA-targeted CAR-T therapy in Q2 2026.
Estimated 2025 market across flow cytometry instruments, reagents and services.
Comparable Outcomes
BioLegend
BioLegend supplied life-science antibodies and reagents spanning cytometry, multiplex assays, recombinant proteins and bioprocessing. PerkinElmer completed the acquisition in September 2021 for approximately $5.25 billion.
PeproTech
PeproTech manufactured recombinant proteins, including cytokines and growth factors, for cell and gene therapy development, manufacturing and broader research. Thermo Fisher completed the acquisition in December 2021 for approximately $1.85 billion.
Interested in More Startups Like BlueRay Precision?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.